Results from NIH-funded study support delaying ovulation induction until after weight loss
Overweight and obese women with polycystic ovary syndrome (PCOS) may have a greater chance of becoming pregnant if they lose weight before beginning fertility treatment, according to an analysis of two studies funded by the National Institutes of Health. It is known that women’s fertility declines with age. These findings support delaying fertility treatment in women with PCOS, even when taking the age-related decline in fertility into account.
PCOS is a condition in which the ovaries often contain numerous small, cyst-like sacs. Along with infertility, symptoms may include obesity; irregular, missing or prolonged menstrual periods; and excessive facial and body hair. Women with PCOS also may experience insulin resistance, a pre-diabetic condition in which higher-than-normal amounts of insulin are produced to maintain normal blood glucose levels.
In one of the analyzed studies, 187 obese and overweight women with PCOS were immediately treated with clomiphene, a drug that induces ovulation. In the other study, 142 women with PCOS began a weight loss program consisting of lower caloric intake, exercise, and anti-obesity medication before starting clomiphene treatment. Women who were treated with clomiphene alone had an ovulation rate of 44.7 percent and a live birth rate of 10.2 percent. The women who received clomiphene after the weight loss program had a 62 percent ovulation rate and a 25 percent live birth rate.
Esther Eisenberg, study author and program director in the Fertility and Infertility Branch at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, is available for interviews.
Legro, R.S., et al, “Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. Journal of Clinical Endocrinology and Metabolism. Published online May 12, 2016. DOI: http://dx.doi.org/10.1210/jc.2016-1659
About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and population issues; and medical rehabilitation. For more information, visit the Institute’s website at http://www.nichd.nih.gov/.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.